The prospects for AIDS vaccines.
Several vaccine strategies against HIV are under study in phase 1 clinical trials. Many involve recombinant subunit preparations, and the question is which of these components of the virus may be immunogenic. Immune effectors and mediators that protect against HIV are also undefined. Vaccines may ultimately be used to treat as well as prevent AIDS.
Koff
W C
WC
Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Md.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002986:Clinical Trials as Topic; D015686:Gene Products, env / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D005814:Genes, Viral / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D011498:Protein Precursors / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins; D014765:Viral Vaccines